
Celea Therapeutics launches into respiratory disease space
PureTech Health has announced the launch of a new founded entity Celea Therapeutics to deliver therapies for serious respiratory diseases. Its lead programme, deupirfenidone (LYT-100), is a Phase III-ready therapeutic candidate that holds promise across multiple fibrotic and inflammatory lung conditions and is initially being advanced for… Read More

